The aim of this competition is to create innovative projects that would not be possible in the same timeframe without the expertise of one another.
We will only fund projects that address one of the following:
1. Explore opportunities from traditional chinese medicine (TCM) for the treatment and/or prevention of infectious diseases in humans and/or animals. The infection being addressed must constitute a significant threat to human health. Improved food security alone will not be sufficient to satisfy the scope requirement.
- combine the use of antibiotics with TCM, herbal medicines and botanicals. A small-scale clinical trial must be included in the project proposal. It should explore the synergy between the use of existing antibiotics. It can include drug repurposing, and TCM agents and practice
- screen and evaluate the active components of TCM herbal remedies and botanicals against bacteria. Sensitising drug resistant bacteria to standard antibiotic regimes will be in scope
2. Advance the discovery of new agents, including small molecule drugs, vaccines, antibodies and other biological products. These agents must be to prevent and/or treat drug resistant bacterial infections in humans and livestock. This includes poultry, and all animals reared for human consumption, provided the second bullet point is fulfilled
- for small molecules, new drug candidates must have a novel mechanism of action and structure
- the infection being addressed must constitute a significant threat to human health as a link to improved food security alone will not meet the competition scope
3. Identify new agents that will increase the feed energy conversion in livestock without using antibiotics or hormones.
4. Using modelling and prospective and retrospective clinical studies, maximise the clinical utility of current antibiotics. Focus especially on those against drug resistant Gram-negative bacteria. Projects must aim to improve the prognosis of patients with extensively drug resistant infections.
5. Improve diagnostic capabilities for the diagnosis, treatment selection and surveillance of bacterial infections and antibacterial resistance.
It is important that you include, or at least work closely with, those who will be commissioning, delivering and using the tests to ensure that target product profiles are fit for purpose. This is important in this competition and particularly for the first and second bullet points.
- the development of rapid diagnostic capabilities (including point-of-care systems, pen-side testing in animals and self testing in humans). Can be for use in primary care, secondary care, the community or home, and on the animal side in the field or abattoir. Laboratory based tests will be in scope with justification that the time to result has clinical utility
- the development of improved diagnostic tools suitable for global surveillance. These can be high throughput laboratory based tests or other
- the identification of new diagnostic biomarkers for distinguishing between bacterial and viral infection and/or determining antibiotic sensitivity. Applicants should note that identifying and validating the candidate biomarkers is the main challenge in this competition. The term biomarker is used in the broadest sense, and includes any physical or biological measurement and their combination in complex algorithms